期刊
YONSEI MEDICAL JOURNAL
卷 62, 期 5, 页码 381-390出版社
YONSEI UNIV COLL MEDICINE
DOI: 10.3349/ymj.2021.62.5.381
关键词
COVID-19; SARS-CoV-2; interferon; interferon-stimulated gene; therapeutics
资金
- 2020 Joint Research Project of Institutes of Science and Technology
COVID-19, caused by SARS-CoV-2, may progress severely due to dysregulation of host IFN responses, but the exact role of IFNs in COVID-19 needs further investigation. Clinical studies are exploring the potential of type I and III IFNs in treating COVID-19.
Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I and III interferon (IFN) responses act as the first line of defense against viral infection and are activated by the recognition of viruses by infected cells and innate immune cells. Dysregulation of host IFN responses has been known to be associated with severe disease progression in COVID-19 patients. However, the reported results are controversial and the roles of IFN responses in COVID-19 need to be investigated further. In the absence of a highly efficacious antiviral drug, clinical studies have evaluated recombinant type I and III IFNs, as they have been successfully used for the treatment of infections caused by two other epidemic coronaviruses, SARS-CoV-1 and Middle East respiratory syndrome (MERS)-CoV. In this review, we describe the strategies by which SARS-CoV-2 evades IFN responses and the dysregulation of host IFN responses in COVID-19 patients. In addition, we discuss the therapeutic potential of type I and III IFNs in COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据